FDA warns Furley Bioextracts over manufacturing failures and unapproved PainFix Relief Gel for the U.S. market.
What happened
FDA reviewed records Furley Bioextracts submitted after FDA's Nov. 5, 2020, request under section 704(a)(4) of the FD&C Act, a records request FDA can use without an inspection. FDA found that PainFix Relief Gel shipped to the U.S. was not tested for menthol identity and strength, incoming active ingredient was not identity-tested, and no stability data supported the labeled expiry. FDA also reviewed the product label and website and found claims showing PainFix Relief Gel was an unapproved new drug and misbranded.
What FDA found
The company did not test each finished batch of PainFix Relief Gel for the identity and strength of menthol before release.
21 CFR 211.165(a)The company did not test incoming active ingredient lots for identity; it relied on the supplier's certificate of analysis (a supplier's test report).
21 CFR 211.84(d)(1)The company had no adequate stability data to support the labeled expiration date for PainFix Relief Gel.
21 CFR 211.137(a)PainFix Relief Gel was an unapproved new drug because it was not generally recognized as safe and effective and no FDA approval was in effect.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)PainFix Relief Gel was misbranded because it did not meet the requirements for marketing under section 505G and had no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)The company lacked process validation, did not qualify equipment, and its batch production records did not document each significant manufacturing step.
21 CFR parts 210 and 211
What FDA wants
FDA tells the company to correct the violations promptly and to reply in writing within 15 working days, specifying corrective and preventive actions; if it cannot finish within 15 working days, it must give reasons and a completion schedule.
Who should pay attention
- brands and distributors selling PainFix Relief Gel in the U.S.
- U.S. importers of OTC drugs from this manufacturer
- quality teams that rely on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.